Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment

Carfilzomib, a proteasome inhibitor, is approved as monotherapy and in combination with dexamethasone or lenalidomide–dexamethasone (Rd) for relapsed or refractory multiple myeloma. The approval of carfilzomib–lenalidomide–dexamethasone (KRd) was based on results from the randomized, phase 3 study A...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Blood Cancer J
Main Authors: Dimopoulos, M A, Stewart, A K, Masszi, T, Špička, I, Oriol, A, Hájek, R, Rosiñol, L, Siegel, D, Mihaylov, G G, Goranova-Marinova, V, Rajnics, P, Suvorov, A, Niesvizky, R, Jakubowiak, A, San-Miguel, J, Ludwig, H, Ro, S, Aggarwal, S, Moreau, P, Palumbo, A
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 2017
Teme:
Original Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5436074/
https://ncbi.nlm.nih.gov/pubmed/28430175
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bcj.2017.31
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki